JP2020526591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526591A5 JP2020526591A5 JP2020523041A JP2020523041A JP2020526591A5 JP 2020526591 A5 JP2020526591 A5 JP 2020526591A5 JP 2020523041 A JP2020523041 A JP 2020523041A JP 2020523041 A JP2020523041 A JP 2020523041A JP 2020526591 A5 JP2020526591 A5 JP 2020526591A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- compound
- disease
- compound according
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 206010027175 memory impairment Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 102100039883 DNA-directed RNA polymerase III subunit RPC5 Human genes 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 1
- 208000025967 Dissociative Identity disease Diseases 0.000 claims 1
- 101000669240 Homo sapiens DNA-directed RNA polymerase III subunit RPC5 Proteins 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 102000003621 TRPC5 Human genes 0.000 claims 1
- 101150042815 TRPC5 gene Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000010457 affective process Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 239000003048 aphrodisiac agent Substances 0.000 claims 1
- 230000002509 aphrodisiac effect Effects 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000005204 segregation Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 0 CC(C)N(c1c(C(N2CCCO)=O)[n](Cc(cc3)cc(F)c3F)c(-c3c(*CC4CC4)nccc3)n1)C2=O Chemical compound CC(C)N(c1c(C(N2CCCO)=O)[n](Cc(cc3)cc(F)c3F)c(-c3c(*CC4CC4)nccc3)n1)C2=O 0.000 description 1
- VENVUGFQRNLDEU-UHFFFAOYSA-N CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3cc(F)cc(F)c3)c(-c(cccn3)c3OCC3CC3)n1)C2=O Chemical compound CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3cc(F)cc(F)c3)c(-c(cccn3)c3OCC3CC3)n1)C2=O VENVUGFQRNLDEU-UHFFFAOYSA-N 0.000 description 1
- LXFRJYSKAMYIHV-UHFFFAOYSA-N CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3ccc(C(F)(F)F)cc3)c(-c(cccn3)c3OCC3CC3)n1)C2=O Chemical compound CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3ccc(C(F)(F)F)cc3)c(-c(cccn3)c3OCC3CC3)n1)C2=O LXFRJYSKAMYIHV-UHFFFAOYSA-N 0.000 description 1
- VHRRZQNQIMXDFL-UHFFFAOYSA-N CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3ccc(C)cc3)c(-c(cccn3)c3OCC3CC3)n1)C2=O Chemical compound CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3ccc(C)cc3)c(-c(cccn3)c3OCC3CC3)n1)C2=O VHRRZQNQIMXDFL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17180721 | 2017-07-11 | ||
| EP17180721.7 | 2017-07-11 | ||
| PCT/EP2018/068366 WO2019011802A1 (en) | 2017-07-11 | 2018-07-06 | NEW SUBSTITUTED XANTHINE DERIVATIVES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526591A JP2020526591A (ja) | 2020-08-31 |
| JP2020526591A5 true JP2020526591A5 (enExample) | 2021-08-12 |
| JP7114702B2 JP7114702B2 (ja) | 2022-08-08 |
Family
ID=59325162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523041A Active JP7114702B2 (ja) | 2017-07-11 | 2018-07-06 | 新規置換キサンチン誘導体 |
Country Status (32)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3761989A4 (en) * | 2018-03-05 | 2021-11-24 | Goldfinch Bio, Inc. | IMIDAZODIAZEPINEDIONE AND METHOD OF USE THEREOF |
| AU2019396499B2 (en) * | 2018-12-12 | 2024-10-10 | Boehringer Ingelheim International Gmbh | Substituted xanthine derivatives |
| EP3894409B1 (en) * | 2018-12-12 | 2023-08-23 | Boehringer Ingelheim International GmbH | Substituted xanthine derivatives |
| EP4037680A4 (en) * | 2019-10-04 | 2023-10-04 | Goldfinch Bio, Inc. | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSSCLEROSIS AND DIABETIC KIDNEY DISEASE |
| WO2024153028A1 (zh) * | 2023-01-20 | 2024-07-25 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
| CN118459461A (zh) * | 2023-02-08 | 2024-08-09 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230384B1 (hu) * | 2001-02-24 | 2016-03-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként |
| US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| ATE496894T1 (de) * | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
| DK2970303T6 (en) * | 2013-03-15 | 2018-10-08 | Hydra Biosciences Inc | SUBSTITUTED XANTHINES AND PROCEDURES FOR USING IT |
| TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位ａ１離子通道 |
| EP3180340B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2016041845A1 (en) | 2014-09-17 | 2016-03-24 | Boehringer Ingelheim International Gmbh | Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes |
-
2018
- 2018-07-06 PL PL18735588T patent/PL3652176T3/pl unknown
- 2018-07-06 EP EP18735588.8A patent/EP3652176B1/en active Active
- 2018-07-06 PE PE2019002691A patent/PE20200861A1/es unknown
- 2018-07-06 SG SG11201912168TA patent/SG11201912168TA/en unknown
- 2018-07-06 MY MYPI2019007689A patent/MY200797A/en unknown
- 2018-07-06 RS RS20211577A patent/RS62826B1/sr unknown
- 2018-07-06 MX MX2020000402A patent/MX394089B/es unknown
- 2018-07-06 HU HUE18735588A patent/HUE057600T2/hu unknown
- 2018-07-06 CN CN201880045961.0A patent/CN110997675B/zh active Active
- 2018-07-06 ES ES18735588T patent/ES2903268T3/es active Active
- 2018-07-06 JP JP2020523041A patent/JP7114702B2/ja active Active
- 2018-07-06 SM SM20220013T patent/SMT202200013T1/it unknown
- 2018-07-06 AU AU2018299824A patent/AU2018299824B2/en active Active
- 2018-07-06 SI SI201830519T patent/SI3652176T1/sl unknown
- 2018-07-06 PT PT187355888T patent/PT3652176T/pt unknown
- 2018-07-06 EA EA202090270A patent/EA039526B1/ru unknown
- 2018-07-06 CA CA3066922A patent/CA3066922A1/en active Pending
- 2018-07-06 KR KR1020207000260A patent/KR102714554B1/ko active Active
- 2018-07-06 UA UAA202000735A patent/UA124793C2/uk unknown
- 2018-07-06 WO PCT/EP2018/068366 patent/WO2019011802A1/en not_active Ceased
- 2018-07-06 LT LTEPPCT/EP2018/068366T patent/LT3652176T/lt unknown
- 2018-07-06 HR HRP20220029TT patent/HRP20220029T1/hr unknown
- 2018-07-06 DK DK18735588.8T patent/DK3652176T3/da active
- 2018-07-06 IL IL271799A patent/IL271799B/en unknown
- 2018-07-10 US US16/031,399 patent/US10329292B2/en active Active
- 2018-07-10 TW TW107123858A patent/TWI801398B/zh active
- 2018-07-11 AR ARP180101931 patent/AR112448A1/es unknown
-
2019
- 2019-12-18 SA SA519410851A patent/SA519410851B1/ar unknown
- 2019-12-30 CO CONC2019/0015102A patent/CO2019015102A2/es unknown
-
2020
- 2020-01-08 CL CL2020000056A patent/CL2020000056A1/es unknown
- 2020-01-10 PH PH12020500079A patent/PH12020500079A1/en unknown
-
2022
- 2022-01-12 CY CY20221100028T patent/CY1125014T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526591A5 (enExample) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2007500757A5 (enExample) | ||
| HRP20220029T1 (hr) | Supstituirani derivati ksantina | |
| SG10201903475TA (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| JP2019512528A5 (enExample) | ||
| ECSP077852A (es) | Compuestos de espiro-oxindol y sus usos como agentes terapéuticos | |
| JP2015512418A5 (enExample) | ||
| TR201904614T4 (en) | Novel pyrazole derivative. | |
| HRP20221240T1 (hr) | Deuterirani analozi etifoksina, njihovi derivati i njihove uporabe | |
| JP2020520911A5 (enExample) | ||
| Kentner | Neuroprotection and recovery from early-life adversity: considerations for environmental enrichment | |
| Memarian et al. | The Effectiveness of laughter yoga exercises on anxiety and sleep quality in the elderly suffering from Parkinson's disease | |
| JP2018522891A5 (enExample) | ||
| WO2020123977A3 (en) | Glial fibrillary acidic protein targeting immuno-and aptamer-based-therapy for neuroinjury, neurodegeneration, neuro-disease, and neuro-repair | |
| Cadet et al. | Methamphetamine-induced psychosis: who says all drug use is reversible | |
| Firouzian et al. | Is ketamine–propofol mixture (ketofol) an appropriate alternative induction agent for electroconvulsive therapy? | |
| JP2017525776A5 (enExample) | ||
| JP2020530846A5 (enExample) | ||
| RU2016152150A (ru) | Ботулинический токсин для применения в лечении паратонии | |
| NO20061559L (no) | Substituerte tienoimidazoler, fremgangsmate for fremstilling og anvendelse derav som medikament eller diagnostikum og medikamenter omfattende de samme | |
| JPWO2020120450A5 (enExample) | ||
| JP2013512279A5 (enExample) | ||
| MX2023003273A (es) | Ligandos de nlrx1. | |
| Rahmatinejad et al. | Efficacy of Transcranial Direct Current Stimulation in Reducing Symptoms in Patients with Major Depressive Disorder: A Randomized Controlled Trial |